Piper Sandler analyst Matt O'Brien notes that Boston Scientific reported full Q4 results, with sales in-line with expectations, while EPS beat by a couple pennies. Management issued 2020 guidance that was in-line on the top-line but a little light on the bottom line, though he believes it is "following its usual conservative script here." The analyst also believes the new product flow will contribute meaningfully to top-line growth, which is "simply hard to bet against in med tech." O'Brien remains constructive on the name and reiterates an Overweight rating and $50 price target on the shares.